Sun Pharma Advanced Research Company Limited (BOM:532872)

Market Cap	48.63B
Revenue (ttm)	717.66M
Net Income (ttm)	-3.43B
Shares Out	n/a
EPS (ttm)	-10.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,322
Average Volume	32,969
Open	151.30
Previous Close	152.00
Day's Range	148.85 - 151.70
52-Week Range	109.20 - 240.95
Beta	n/a
RSI	36.83
Earnings Date	Aug 4, 2025

About Accolade

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoria...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 316
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532872

Financial Performance

In 2024, BOM:532872's revenue was 717.66 million, a decrease of -5.00% compared to the previous year's 755.45 million. Losses were -3.43 billion, -11.55% less than in 2023.